Kashiv BioSciences and CRISTÁLIA Enter into Licensing and Supply Agreement for Omalizumab Biosimilar (ADL-018) in Latin America

Posted by By JP jplive24 0 Min Read
712424d2 1791 462f 981e 7c59eecd8cbc 150x150 1

Business Wire India Kashiv BioSciences, LLC (“Kashiv” or the “Company”) today announced that it has entered into a licensing and supply agreement with CRISTÁLIA, one of the leading pharmaceutical companies in Brazil, for the commercialization of ADL-018 / bOmalizumab, a proposed biosimilar to Xolair®, in Latin America (LATAM). In 2024,

Tap to Read More.....

ALSO READ -  Globalart Enters Eastern India with Its First Centre in KolkataIndia’s Largest Chain of Art Centres Expands Footprint to the Cultural Capital
Translate »